Abstract
An emerging new technology based on genetic engineering of viral vectors that can insert genes into the cells of living organisms may play a significant role in treating disorders of the central nervous system (CNS). Most neurodegenerative disorders affect focal regions of the brain. Preventive and/ or palliative treatment strategies need to be targeted only to the diseased parts of the brain without affecting other regions. Administration of therapeutic genes specifically to the disease-affected regions of the brain may be more beneficial than current treatment strategies, which are largely based on systemically administering small molecules. The latter can result not only in peripheral side effects but also CNS side effects since the drugs can affect both targeted and nontargeted brain sites. In addition, many therapeutic agents are prevented from entering the brain by the blood-brain barrier (BBB). For these reasons, many otherwise potentially useful proteins, such as trophic factors, cannot be administered systemically (1)
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Kordower, J. H., Palfi, S., Chen, E. Y., Ma, S. Y., Sendera, T., Cochran, E. J., et al. (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann. Neurol. 46, 419–424.
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., et al. (1995) Mesencephalic dopaminergic neurons protected by GDNF from axotomyinduced degeneration in the adult brain. Nature 373, 339–341.
Hyman, C., Hofer, M., Barde, Y. A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., et al. (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350, 230–232.
Hoffer, B. J., Hoffman, A., Bowenkamp, K., Huettl, P., Hudson, J., Lin, L. F., et al. (1994) Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci. Lett. 182, 107–111.
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S., and Collins, F. (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130–1132.
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., et al. (1996) Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 380, 252–255.
Sauer, H., Rosenblad, C., and Bjorklund, A. (1995) Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. USA 92, 8935–8939.
Horger, B., Nishimura, M., Armanini, M., Wang, L.-C., Poulsen, K., et al. (1998) Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J. Neurosci. 18, 4929–4937.
Milbrandt, J., deSauvage, F. J., Fahrner, T. J., Baloh, R. H., et al. (1998) Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20, 245–253.
Bankiewicz, K. S., Bringas, J., Pivirotto, P., Kutzscher, E., Nagy, D., Emborg, M. E. Technique for bilateral intracranial implantation of cells in monkeys using an automated delivery system. Cell Transplant 9, 595–607.
Tuszynski, M. H., Senut, M. C., Ray, J., Roberts, J., Hoi-Sang, U.,and Gage, F. H. (1994) Somatic gene transfer to the adult primate central nervous system: in vitro and in vivo characterization of cells genetically modified to secrete nerve growth factor. Neurobiol. Dis. 1, 67–78.
Schinstine, M., Jasodhara, R., and Gage, F. H. (1997) Potential effects of cytokines on transgene expression in primary fibroblasts implanted into rat brain. Mol. Brain Res. 47, 195–201.
Major, E. O., Miller, A. E., Mourrain, P., Traub, R. G., de Widt, E., and Sever, J. (1985) Establishment of a line of human fetal glial cells which supports JC virus multiplication. Proc. Natl. Acad. Sci. 82, 1257–1261.
Tornatore, C., Bankiewicz, K., Lieberman, D., and Major, E. O. (1993) Implantation and survival of a human fetal brain derived cell line in the basal ganglia of the non-human primate, rhesus monkey. J. Cell Biochem. 17E, 227.
Bankiewicz, K. S., Leff, S., Nagy, D., Jungles, S., Rokovich, J, Spratt, K., Cohen, L., et al. (1997) Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson’s disease. Exp. Neurol. 144, 147–156.
Quereshi, N. H., Bankiewicz, K. S., Louis, D. N., Hochberg, F., Chiocca, A., and Harsh, G. R. (2000) Multicolumn infusion of gene therapy cells into human brain tumors: technical report. Neurosurgery 46, 633–669.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Bankiewicz, K.S., Pivirotto, P., Sanchez-Pernaute, R., Major, E.O. (2001). Grafting Genetically Engineered Cells into the Striatum of Nonhuman Primates. In: Maral Mouradian, M. (eds) Parkinson's Disease. Methods in Molecular Medicine™, vol 62. Humana Press. https://doi.org/10.1385/1-59259-142-6:269
Download citation
DOI: https://doi.org/10.1385/1-59259-142-6:269
Publisher Name: Humana Press
Print ISBN: 978-0-89603-761-8
Online ISBN: 978-1-59259-142-8
eBook Packages: Springer Protocols